DEX Stock Overview
Dextech Medical AB develops drug candidates for application in urological oncology, primarily for prostate cancer.
Dextech Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr4.08|
|52 Week High||kr33.20|
|52 Week Low||kr4.08|
|1 Month Change||-16.90%|
|3 Month Change||-37.23%|
|1 Year Change||-87.71%|
|3 Year Change||-94.52%|
|5 Year Change||-85.43%|
|Change since IPO||-59.20%|
Recent News & Updates
Dextech Medical (NGM:DEX) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|DEX||SE Biotechs||SE Market|
Return vs Industry: DEX underperformed the Swedish Biotechs industry which returned -22.1% over the past year.
Return vs Market: DEX underperformed the Swedish Market which returned -22% over the past year.
|DEX Average Weekly Movement||6.3%|
|Biotechs Industry Average Movement||9.7%|
|Market Average Movement||7.3%|
|10% most volatile stocks in SE Market||12.9%|
|10% least volatile stocks in SE Market||4.6%|
Stable Share Price: DEX is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: DEX's weekly volatility (6%) has been stable over the past year.
About the Company
Dextech Medical AB develops drug candidates for application in urological oncology, primarily for prostate cancer. Its principal product candidate is OsteoDex that has completed phase IIb clinical trial for the treatment of skeletal metastases in castration resistant prostate cancer, as well as in preclinical stage to treat breast cancer. The company is also developing SomaDex, a drug candidate that is based on somatostatin body hormone to treat acromegaly, neuroendocrine tumors, and palliative therapy in advanced prostate cancer; CatDex, a preclinical stage drug candidate for instillation therapy of superficial bladder cancer; and PSMADex, a preclinical stage drug candidate that is used as a carrier molecule for the treatment of cancer expressing prostate-specific membrane antigen.
Dextech Medical Fundamentals Summary
|DEX fundamental statistics|
Is DEX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DEX income statement (TTM)|
|Cost of Revenue||kr1.51m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 30, 2022
|Earnings per share (EPS)||-0.25|
|Net Profit Margin||-1,200.13%|
How did DEX perform over the long term?See historical performance and comparison
Is DEX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DEX?
Other financial metrics that can be useful for relative valuation.
|What is DEX's n/a Ratio?|
Price to Book Ratio vs Peers
How does DEX's PB Ratio compare to its peers?
|DEX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
SPAGO Spago Nanomedical
PROMO Promore Pharma
ACTI Active Biotech
PROGEN Prostatype Genomics
DEX Dextech Medical
Price-To-Book vs Peers: DEX is good value based on its Price-To-Book Ratio (1.8x) compared to the peer average (5.3x).
Price to Earnings Ratio vs Industry
How does DEX's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: DEX is good value based on its Price-To-Book Ratio (1.8x) compared to the Swedish Biotechs industry average (2.3x)
Price to Book Ratio vs Fair Ratio
What is DEX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.8x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate DEX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of DEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DEX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DEX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Dextech Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dextech Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Dextech Medical's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
How has Dextech Medical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DEX is currently unprofitable.
Growing Profit Margin: DEX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DEX is unprofitable, but has reduced losses over the past 5 years at a rate of 8.7% per year.
Accelerating Growth: Unable to compare DEX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DEX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).
Return on Equity
High ROE: DEX has a negative Return on Equity (-11.48%), as it is currently unprofitable.
Discover strong past performing companies
How is Dextech Medical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: DEX's short term assets (SEK39.3M) exceed its short term liabilities (SEK200.0K).
Long Term Liabilities: DEX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: DEX is debt free.
Reducing Debt: DEX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DEX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DEX has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 23.3% each year
Discover healthy companies
What is Dextech Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DEX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DEX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DEX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DEX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as DEX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Anders Holmberg (71 yo)
Mr. Anders R. Holmberg, M.D. is the Founder of Dextech Medical AB (publ) and serves as its Chief Executive Officer and Managing Director and served as its President. Mr. Holmberg has been a Director at Dex...
Experienced Management: DEX's management team is seasoned and experienced (18.6 years average tenure).
Experienced Board: DEX's board of directors are considered experienced (9.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.9%.
Dextech Medical AB's employee growth, exchange listings and data sources
- Name: Dextech Medical AB
- Ticker: DEX
- Exchange: NGM
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr78.565m
- Shares outstanding: 18.49m
- Website: https://www.dextechmedical.com
Number of Employees
- Dextech Medical AB
- Dag HammarskjOelds VAeg 34A
- Uppsala County
- 752 37
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/09 00:00|
|End of Day Share Price||2022/08/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.